Comparative Safety Profile of Levofloxacin in 2523 Children With a Focus on Four Specific Musculoskeletal Disorders

@article{Noel2007ComparativeSP,
  title={Comparative Safety Profile of Levofloxacin in 2523 Children With a Focus on Four Specific Musculoskeletal Disorders},
  author={Gary J Noel and John S Bradley and Ralph E. Kauffman and Ciar{\'a}n M. Duffy and Peter G. Gerbino and Adriano G Arguedas and Partha Bagchi and Dainius A. Balis and Jeffrey L. Blumer},
  journal={The Pediatric Infectious Disease Journal},
  year={2007},
  volume={26},
  pages={879-891}
}
Background: Fluoroquinolones, including levofloxacin, have not been recommended for use in children largely because studies in juvenile laboratory animals suggest there may be an increased risk of fluoroquinolone-associated cartilage lesions. A large prospective trial is needed to assess the risks associated with using levofloxacin in children. Objective: Assess the safety and tolerability of levofloxacin therapy in children based on observations for 1 year after therapy. Methods: Safety data… Expand
Assessment of Musculoskeletal Toxicity 5 Years After Therapy With Levofloxacin
TLDR
Risks of cartilage injury with levofloxacin appear to be uncommon, are clinically undetectable during 5 years, or are reversible, according to this 5-year follow-up safety study on musculoskeletal adverse events presenting between 1 and 5 years. Expand
Fluoroquinolones in Children With Fever and Neutropenia: A Systematic Review of Prospective Trials
TLDR
Fluoroquinolones can be comfortably adopted for low- risk FN, although experience in high-risk FN is uncertain in pediatrics, although reported studies have been restricted to low-risk patients. Expand
Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data.
TLDR
Only life-threatening infections for which other antimicrobials cannot be used are possible indications for quinolones in children, for example the use of ciprofloxacin in cystic fibrosis patients with a bronchopulmonary exacerbation, chronic suppurative otitis media caused by Pseudomonas sp. Expand
Assessment of the risk of musculoskeletal adverse events associated with fluoroquinolone use in children
TLDR
The results showed that fluoroquinolone and non-fluoroquinlone antibiotics were not different in terms of their ability to cause musculoskeletal adverse events in children. Expand
Fluoroquinolones in pediatrics: review of hospital prescription use over 2 years.
TLDR
This is the first study to collect so much data on FQ prescriptions for hospitalized children and use in practice went beyond the licensed indication, and doses were consistent with those for recommended indications. Expand
The Risk of Musculoskeletal Adverse Events With Fluoroquinolones in Children
TLDR
The purpose of this article is to examine the evidence on MAEs associated with fluoroquinolones and to provide guidance to clinicians on whether the risks of MAEs outweigh the benefits in the pediatric population. Expand
Fluoroquinolones in children: update of the literature
TLDR
Considering the increased use of FQ in children, it is possible that there is an increase in the incidence of infections from resistant germs (such as Escherichia coli, and pneumococci), as occurred in adults, and a judicious and appropriate use of this class of drugs is recommended. Expand
Systemic use of fluoroquinolone in children
TLDR
An updated review on the safety and current recommendations for using fluoroquinolones in children and how they may be particularly helpful in treating multidrug-resistant infections that have not responded to standard antibiotic therapy in immunocompromised patients is provided. Expand
Appropriate use of fluoroquinolones in children.
TLDR
The use of FQs should be limited to selected respiratory infections, exacerbation of lung disease in cystic fibrosis, central nervous system infections, enteric infections, febrile neutropenia, as well as serious infections attributable to FQ-susceptible pathogen(s) in children with life-threatening allergies to alternative agents. Expand
Safety Concerns Surrounding Quinolone Use in Children
TLDR
The pharmacological properties of fluoroquinolones are highlighted and their current use in pediatrics is described and a comprehensive assessment of the safetyData demonstrate that arthralgia and arthropathy are relatively uncommon in children and resolve following cessation of fluoquinolone exposure without resulting in long‐term sequelae. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin
TLDR
In this observational study involving more than 6000 FQ-treated children, the incidence of TJD associated with selected FQ use in children was <1% and was comparable with that of the reference group, children treated with AZ. Expand
Safety profile of quinolone antibiotics in the pediatric population.
  • R. Grady
  • Medicine
  • The Pediatric infectious disease journal
  • 2003
TLDR
A review of retrospective and prospective safety data of ciprofloxacin-treated children showed that the rates of arthralgia and quinolone-induced cartilage toxicity were low and the role of fluoroquinolones in the treatment of certain serious infections in children does not appear to be compromised by safety concerns when used appropriately. Expand
Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France.
TLDR
The rates of PAEs and musculoskeletal PAEs were higher for the FQ group than the control group, which supports the American Academy of Pediatrics statement restricting off-label FQ use in pediatric patients to second-line treatment in a limited number of situations. Expand
Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure.
TLDR
Gatifloxacin appears to be safe for children, with no evidence of producing arthrotoxicity in 867 children exposed to the antibiotic when used as treatment for ROM and AOMTF. Expand
An Open-Label, Double Tympanocentesis Study of Levofloxacin Therapy in Children With, or at High Risk for, Recurrent or Persistent Acute Otitis Media
TLDR
Levofloxacin was safe and effective in treating and eradicating common bacterial pathogens from MEF in children with, or at risk for, recurrent or persistent otitis media. Expand
Levofloxacin Pharmacokinetics in Children
TLDR
To provide compatible levofloxacin exposures associated with clinical effectiveness and safety in adults, children <5 years need a daily dose of 10 mg/kg, whereas children 6 months to<5 years should receive 10mg/kg every 12 hours. Expand
Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure
TLDR
Gatifloxacin is safe and effective for treatment of recurrent otitis media and AOM treatment failure in children, and eighty-three percent of the children had sustained cure at the 4 weeks follow-up visit. Expand
Pediatric urinary tract infections: the role of fluoroquinolones
TLDR
Oral fluoroquinolones are an attractive alternative for the treatment of complicated UTI in children, and safety must always be a factor in considering their use in this population. Expand
Quinolone arthropathy in animals versus children.
The use of quinolones in children and accumulation of data on the pharmacodynamics of these drugs have been limited and delayed by concern regarding their chondrotoxicity. A comprehensive review ofExpand
Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
  • M. E. Ernst, E. Ernst, M. Klepser
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 1997
TLDR
Levofloxacin and trovafloxACin have favorable antimicrobial and pharmacokinetic profiles, offering the advantages of once-daily doses as well as superior potency and spectrum of activity compared with currently available quinolones. Expand
...
1
2
...